February 7th 2025
This combination antibiotic is indicated for adults with limited or no treatment options, including gram-negative infections. It will be available in the third quarter of this year.
Challenges in the Management of Mycobacterium abscessus Complex
This pathogen is the third most frequently isolated nontuberculous mycobacteria seen in the United States. Here is a review of how it presents and treatment options.
Read More
FDA Approval of First Fecal Microbiota Product Ensures Safety in Standardization
December 7th 2022Ferring Chief Scientific Officer Dr. Elizabeth Garner explains the FDA approval of recurrent C diff treatment RBX2660 provides more than a treatment option, it’s a promise of safety and standardization.
Watch
The Confluence of New Antibiotics, Treatment Guidelines, and Antimicrobial Stewardship in SSTIs
December 6th 2022With the proliferation of therapies for skin and soft tissue infections (SSTIs), a clinician discusses how providers can appropriately find the balance between these novel therapies, the existing treatment guidelines, and stewardship.
Watch